Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
bluebird bio (GB:0HOH)
LSE:0HOH
Holding GB:0HOH?
Track your performance easily
0HOH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.46 - $5.53
Previous Close$0.51
Volume7.70K
Average Volume (3M)45.17K
Market Cap
$96.96M
Enterprise Value$299.25M
Total Cash (Recent Filing)$212.05M
Total Debt (Recent Filing)$414.34M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Nov 05, 2024EPS Estimate
-$0.37Last Dividend Ex-Date
Nov 05, 2021Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding193,913,585
10 Day Avg. Volume31,985
30 Day Avg. Volume45,166
Standard Deviation0.23
R-Squared0.02
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.69
Price to Sales (P/S)2.56
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.55
Enterprise Value/Gross Profit-74.26
Enterprise Value/Ebitda-1.19
Forecast
1Y Price Target
$4.00Price Target Upside726.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Bluebird Bio News
PremiumCompany Announcements
Bluebird Bio Announces Restructuring and Targets Break-Even
PremiumCompany Announcements
Bluebird Bio Works to Resolve Financial Reporting Delays
Bulls Say, Bears Say
Bulls Say
Manufacturing ExpansionManagement shared that its product launches have accelerated due to its growth of QTCs (71 have been activated) and its recent manufacturing expansion at its Lonza facility, which will double its manufacturing capacity for Zynteglo and Skysona production.
Patient StartsThere have been 41 patient starts across BLUE's portfolio, which is up from 27 reported in the previous update.
RestructuringBLUE announced that it is implementing a restructuring that is intended to optimize its cost structure and enable quarterly cash flow break-even.
Bears Say
FinancingThe company will still need to obtain additional cash resources to achieve cash flow breakeven in the second half of 2025 as its current cash and cash equivalents are expected to be sufficient to fund operations only into the second quarter of 2025.
Product PerformanceLonger-than-expected processing time for Zynteglo (now 100-120 days vs 70-90 days previously) could contribute to longer lead times.
RevenueManagement indicated that it anticipates a drop in total revenue in 3Q.
---
Options Prices
Currently, No data available
---
Ownership Overview
4.92% Insiders
15.53% Mutual Funds
16.41% Other Institutional Investors
63.14% Public Companies and
Individual Investors
0HOH FAQ
What was bluebird bio’s price range in the past 12 months?
bluebird bio lowest share price was $0.46 and its highest was $5.53 in the past 12 months.
What is bluebird bio’s market cap?
Currently, no data Available
When is bluebird bio’s upcoming earnings report date?
bluebird bio’s upcoming earnings report date is Nov 05, 2024 which is in 40 days.
How were bluebird bio’s earnings last quarter?
bluebird bio released its earnings results on Aug 14, 2024. The company reported -$0.389 earnings per share for the quarter, beating the consensus estimate of -$0.417 by $0.028.
Is bluebird bio overvalued?
According to Wall Street analysts bluebird bio’s price is currently Undervalued.
Does bluebird bio pay dividends?
bluebird bio pays a Notavailable dividend of $8.88 which represents an annual dividend yield of N/A. See more information on bluebird bio dividends here
What is bluebird bio’s EPS estimate?
bluebird bio’s EPS estimate is -$0.37.
How many shares outstanding does bluebird bio have?
bluebird bio has 193,913,590 shares outstanding.
What happened to bluebird bio’s price movement after its last earnings report?
bluebird bio reported an EPS of -$0.389 in its last earnings report, beating expectations of -$0.417. Following the earnings report the stock price went down -20.865%.
Which hedge fund is a major shareholder of bluebird bio?
Among the largest hedge funds holding bluebird bio’s share is Woodline Partners LP. It holds bluebird bio’s shares valued at 954K.
---
Bluebird Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (726.45% Upside)
$4.00 (726.45% Upside)
Blogger Sentiment
Bullish
GB:0HOH Sentiment 83%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.22%
12-Months-Change
Fundamentals
Return on Equity
-121.56%
Trailing 12-Months
Asset Growth
-8.84%
Trailing 12-Months
Company Description
bluebird bio
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.
---
0HOH Earnings Call
Q2 2024
0:00 / 0:00
---
0HOH Stock 12 Month Forecast
Average Price Target
$4.00
▲(726.45% Upside)
Technical Analysis
Bluebird Bio
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Sangamo Biosciences
―
Best Analysts Covering 0HOH
1 Year
1 Year Success Rate
8/15 ratings generated profit
1 Year Average Return
+13.51%
reiterated a sell rating 5 months ago
Copying Salveen Richter's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +13.51% per trade.
---